News Exscientia builds cancer pipeline with two BMS drugs LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Rumour of Pfizer, Seagen deal is true, with $43bn price tag Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.
News Despite FDA doubts, advisors back first-line Polivy use Panel votes 11 to 2 to back Roche's drug for treatment-naïve diffuse large B-cell lymphoma.
R&D Allogeneic therapies: The future of cancer treatment? Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.
News Could VR therapy improve mental health in cancer patients? Study is testing a VR DTx developed by Rocket VR Health and Massachusetts General Hospital.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
